Abridged Regulatory Pathways

Why It Matters

Bridged reliance pathways enable quicker, cost‑effective approvals by leveraging PMDA assessments, accelerating patient access to innovative therapies worldwide.

Key Takeaways

• Reliance reduces duplication, boosting regulatory efficiency across nations.
• Bridged pathways use reference authority assessments to shorten timelines.
• PMDA offers English translations of review reports for global stakeholders.
• Applicants must certify translation authenticity when requested by regulators.
• Access to PMDA data improves safety monitoring and market entry.

Summary

The video explains the concept of bridged regulatory pathways, a reliance‑based model that lets national regulatory authorities (NRAs) base decisions on assessments performed by a reference agency such as Japan’s PMDA. The World Health Organization defines reliance as a means to streamline regulation, improve access to safe medical products, and avoid duplicated work across jurisdictions.

Key points include the WHO’s two‑fold merit of reliance: greater operational efficiency for the relying NRA and reduced redundancy for the reference authority. By adopting a bridged pathway, a regulator can incorporate a PMDA review—often accompanied by Japanese clinical data and post‑marketing safety information—into its own assessment, cutting both time and resource demands while preserving oversight standards.

The PMDA has instituted a practical scheme: applicants submit an English translation of the PMDA review report, a cover letter, and the dossier to the relying authority. Regulators may query the PMDA directly, limiting inquiries to the applicant and accelerating decisions. When only a Japanese version exists, the applicant translates the entire document or supplements existing English excerpts, and may provide a third‑party certification of translation authenticity if required.

For industry, this reliance framework promises faster market entry, lower development costs, and broader access to high‑quality data. For regulators, it offers a scalable way to keep pace with innovative therapies while maintaining rigorous safety standards, positioning Japan as a trusted reference market in the global regulatory ecosystem.

Original Description

This video shows PMDA's collaboration with foreign regulatory authorities in promoting abridged regulatory pathways. It includes benefits of referring to PMDA reports, the way to prepare its English translations, and other useful information for regulators.